DeepMed Research

Sonolisib

Generic Name: Sonolisib

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₅NO_₈

CAS Number: 502632-66-8

Unique Ingredient Identifier: 987796874T

Background: Sonolisib has been used in trials studying the treatment of Glioblastoma, Prostate Cancer, Advanced Solid Tumors, Advanced BRAF-mutant Cancers, and Non Small Cell Lung Cancer (NSCLC), among others.

Clinical Trials

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Phase 1

Terminated

Conditions: Advanced BRAF-mutant Cancers

Interventions: Drug: PX-866
Drug: vemurafenib

First Posted Date: 2012-06-11

Last Posted Date: 2018-05-16

Lead Sponsor: Cascadian Therapeutics Inc.

Target Recruit Count: 24

Registration Number: NCT01616199

Locations: 🇺🇸
New York University, New York, New York, United States
🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States

and more 2 locations

Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: PX-866

First Posted Date: 2011-08-03

Last Posted Date: 2018-05-17

Lead Sponsor: Cascadian Therapeutics Inc.

Target Recruit Count: 39

Registration Number: NCT01408316

Locations: 🇺🇸
Comprehensive Clinical Development NW, Tacoma, Washington, United States

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: PX-866

First Posted Date: 2011-04-07

Last Posted Date: 2023-08-22

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 68

Registration Number: NCT01331083

Locations: 🇨🇦
London Regional Cancer Program, London, Ontario, Canada
🇨🇦
Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada
🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada

and more 7 locations

A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression

Phase 2

Completed

Conditions: Glioblastoma

Interventions: Drug: PX-866

First Posted Date: 2010-12-14

Last Posted Date: 2023-08-22

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 34

Registration Number: NCT01259869

Locations: 🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇨🇦
London Regional Cancer Program, London, Ontario, Canada
🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada

and more 4 locations

Study of PX-866 and Docetaxel in Solid Tumors

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer (NSCLC)
Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Interventions: Drug: Docetaxel
Drug: PX-866

First Posted Date: 2010-09-17

Last Posted Date: 2018-05-16

Lead Sponsor: Cascadian Therapeutics Inc.

Target Recruit Count: 223

Registration Number: NCT01204099

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇨🇦
CHUS Hopital Fleurimont, Sherbrooke, Quebec, Canada
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

and more 30 locations

Phase I Trial of Oral PX-866

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: PX-866

First Posted Date: 2008-08-01

Last Posted Date: 2018-05-17

Lead Sponsor: Cascadian Therapeutics Inc.

Target Recruit Count: 90

Registration Number: NCT00726583

Locations: 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Colorado Health Sciences Center, Aurora, Colorado, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy